ALT Stock — Altimmune Inc.: Cash, EV, Pipeline

Share price

$3.25

Market cap

$632.2M

Cash

$326.3M

Enterprise value

$340.6M

Balance sheet

Cash	$326.3M
Debt	$34.7M
Net cash	$291.6M
Enterprise value	$340.6M
Basic shares	194.5M shares
Fully diluted shares	284.3M shares
Fully diluted market cap	$923.9M
Cash per share	$1.68

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ALT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 11 - Dec 23	Pemvidutide	Phase 2	Alcohol-associated Liver Disease	—
Jan 12 - Feb 23	Pemvidutide	Phase 3	Metabolic Dysfunction-Associated Steatohepatitis (MASH)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Pemvidutide

Phase 3 · Active Modality: peptide

Aliases ALT-801

Target glucagon receptor / GLP-1 receptor (dual agonist)

Partnerships Mederis Diabetes, LLC: exclusive licensee of EuPort-domain incretin peptide IP (covers pemvidutide); economics not disclosed

Indications

MASH (moderate to advanced fibrosis) (Phase 3)
Alcohol use disorder (AUD) (Phase 2)
Alcohol-associated liver disease (ALD) (Phase 2)

Catalysts

— 2029

Status note Lead product candidate per this filing. PERFORMA registrational Phase 3 in MASH began enrolling Aug 3, 2026. IMPACT Phase 2b MASH 48-week topline reported Dec 2025; RECLAIM Phase 2 AUD topline reported Jul 28, 2026 (End-of-Phase 2 meeting planned); RESTORE Phase 2 ALD enrollment completed Jul 2026. Breakthrough Therapy Designation for MASH (Jan 2026); Fast Track for AUD (Aug 2025).

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Pemvidutide
Lead indication	Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07795164	Phase 3	Recruiting	Sponsor	ALT	—	Metabolic Dysfunction-Associated Steatohepatitis (MASH)	—
NCT07009860	Phase 2	Active, not recruiting	Sponsor	ALT	—	Alcohol-associated Liver Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Altimmune, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	102,823	+102,823	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ALT — Altimmune Inc.